News

December 10, 2019December 16, 2019

Advanced Multiple Myeloma Patients Responding to Janssen’s CAR T-cell Therapy, Trial Data Show

News

Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or refractory multiple myeloma treated in ... Read more

December 9, 2019December 9, 2019

Kyprolis Combo Followed by Stem Cell Transplant is Effective for Most Smoldering Multiple Myeloma, Data Show

News

A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after a stem cell transplant, is effective for the treatment of patients with smoldering multiple myeloma ... Read more

December 6, 2019December 6, 2019

Ninlaro Triple Combo Delays Progression of High-Risk Smoldering Multiple Myeloma, Trial Suggests

News

Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple myeloma — a precursor of multiple myeloma — is safe ... Read more

December 4, 2019December 12, 2019

Venclexta-Darzalex Combos Show Strong Response Rates in Multiple Myeloma Trial, Early Data Show

News

Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who failed prior treatment, particularly those with a common ... Read more

December 3, 2019December 4, 2019

Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show

News

Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality ... Read more

December 2, 2019December 2, 2019

Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces

News

Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. ... Read more

November 27, 2019November 27, 2019

AbbVie Obtains Global Rights Option for HPN217, Phase 1/2 Trial in Multiple Myeloma Planned

News

Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion of an anticipated Phase 1/2 trial. ... Read more

November 25, 2019November 25, 2019

BiCNU Generic for Multiple Myeloma, Other Cancers Launched in US

News

Carmustine for Injection, a generic version of the chemotherapy BiCNU, has been launched in the U.S to treat people with multiple myeloma and other types of cancer. This follows ... Read more

November 22, 2019November 22, 2019

Darzalex Triple Combo Approved in Europe for Myeloma Patients Ineligible for ASCT

News

The European Commission has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for adults with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The decision was supported ... Read more

November 20, 2019November 20, 2019

First Multiple Myeloma Patient Dosed With CAR T-Cell Therapy UCARTCS1 in Phase 1 Trial

News

The donor-derived, or allogeneic CAR T-cell therapy candidate UCARTCS1 has been administrated to the first patient in an ongoing Phase 1 trial for relapsed/refractory multiple myeloma. The study (NCT04142619), ... Read more

Pin It on Pinterest